Pelacarsen sodium
Highest phase reached
Phase 1
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Oligonucleotide
- Drug name
- Pelacarsen sodium
- akcea apo a lrx salt
- AKCEA-APO(a)-LRx salt
- isis 681257
- isis 681257 galnac3 conjugated aso targeting human lipoprotein a
- isis 681257 salt
- ISIS 681257 salt
- isis 681257 sodium
- ISIS-681257
- ISIS-681257 (GALNAC3--CONJUGATED ASO TARGETING HUMAN LIPOPROTEIN (A) )
- ISIS-681257 SODIUM
- pelacarsen sodium
- Pelacarsen sodium
- PELACARSEN SODIUM [USAN]
- pelacarsen sodium usan
- CAS registry numbers
- 2172851-58-8
- ChEMBL ID
- CHEMBL4298203
- FDA ingredient codes (UNII)
- D1J27662O8
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -rsen
Investigated indications
- Condition
- Coronary Artery Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001645
- Subject identifier
- D003324
- Condition identifier
- EFO_0001645
- Condition identifier
- MONDO_0005010
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Sequences
- Component
- Sequence
- Type
- Nucleic Acid
- Sequence
- 20Na+ [(3'-5')R1-U=G-C-U-C-d(C=G=T=T=G=G=T=G=C=T=)U-G-U=U=C]20-
Related records
Trials (15)
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany
- A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants
- An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin
- Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)
- Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
- Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
- Managed Access Programs for TQJ230, Pelacarsen
- Pelacarsen Roll-over Extension Program
- Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
- Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients
- Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants
In development for (1)
- Coronary artery disorder Phase 1